Johnson & Johnson (J&J; NYSE: JNJ) has finalized the acquisition of medical device manufacturer Laminar for $400 million, along with potential milestone payments, integrating the company into its MedTech subsidiary, specifically within Biosense Webster, a division focused on heart rhythm disorders.
Laminar’s innovative technology employs rotational motion to eliminate the left atrial appendage (LAA), significantly reducing stroke risk in patients suffering from non-valvular atrial fibrillation (AFib), a condition impacting an estimated 38 million individuals worldwide. This groundbreaking method circumvents the need for long-term anticoagulants or catheter-based LAA-plugging procedures, with clinical development expected to commence next year.
The acquisition will incur a research and development charge, leading to reductions in J&J’s adjusted earnings per share (EPS) of $0.17 and $0.15 for the fiscal years 2023 and 2024, respectively.- Flcube.com
